TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03741049

Intervention type: DEVICE
Intervention: Seldinger technique (plastic laryngeal model)
Description: Melker Set

Intervention type: DEVICE
Intervention: Surgical technique (plastic laryngeal model)
Description: Scalpel and speculum

Intervention type: DEVICE
Intervention: Surgical technique (plastic laryngeal model)
Description: Scalpel and speculum
Study: NCT04830059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air purification
Description: Air purification in order to reduce the PM2.5 and PM10
Study: NCT05775952

Intervention type: BIOLOGICAL
Intervention: HRV-39
Description: We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.

Intervention type: BIOLOGICAL
Intervention: HRV-39
Description: We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
Study: NCT01560650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRRT
Description: Difference dose of CRRT
Study: NCT03741049

Intervention type: DEVICE
Intervention: Surgical technique (plastic laryngeal model)
Description: Scalpel and speculum

Intervention type: DEVICE
Intervention: Surgical technique (plastic laryngeal model)
Description: Scalpel and speculum
Study: NCT03782909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Description: The behaviour change intervention consists of;~1. Feedback via an app based food diary~2. Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it
Study: NCT02188186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initial triple combination
Description: Initial triple combination arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventioanl treament with dose escalation
Study: NCT03678285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFRT Workout
Description: A single high intensity functional resistance training (HIFRT) exercise bout.
Study: NCT02346266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMART Education
Study: NCT02527538

Intervention type: DEVICE
Intervention: Pleth
Description: apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
Study: NCT01258712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab + methotrexate(MTX)
Description: Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab placebo + methotrexate(MTX)
Description: Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
Study: NCT02602600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: * Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks
Study: NCT03053401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
Study: NCT03404219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and Skills Support (MASS)
Description: Mobile phone-based application to support social skills and social motivation
Study: NCT01072240

Intervention type: DRUG
Intervention: rituximab [Mabthera/Rituxan]
Description: As prescribed by physician
Study: NCT00732238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened course of antibiotic therapy
Description: By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
Study: NCT00858481

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spinosad Creme Rinse - Vehicle Control
Description: One or two, 10-minute topical applications (7 days apart)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinosad Creme Rinse
Description: 0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
Study: NCT03741049

Intervention type: DEVICE
Intervention: Scalpel Bougie technique (porcine laryngeal model)
Description: ScalpelCric Set

Intervention type: DEVICE
Intervention: Scalpel Bougie technique (porcine laryngeal model)
Description: ScalpelCric Set

Intervention type: DEVICE
Intervention: Surgical technique (porcine laryngeal model)
Description: Scalpel and speculum

Intervention type: DEVICE
Intervention: Surgical technique (porcine laryngeal model)
Description: Scalpel and speculum
Study: NCT00622856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological intervention
Description: Psychological intervention
Study: NCT00858481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinosad Creme Rinse
Description: 1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinosad Creme Rinse
Description: 2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
Study: NCT00990860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE (Transcatheter arterial chemoembolization)
Description: TACE (Transcatheter arterial chemoembolization)
Study: NCT02750748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study: NCT00732238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
Study: NCT02750748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravail
Study: NCT03555006

Intervention type: OTHER
Group type: OTHER
Intervention: Dual ultrasound reading local vs remote
Description: The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.

Intervention type: OTHER
Group type: OTHER
Intervention: Dual ultrasound reading local vs local
Description: The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
Study: NCT05050110

Intervention type: OTHER
Group type: OTHER
Intervention: Fruits and Vegetable increase
Description: Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
Study: NCT03429400

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Sulfate
Description: Morphine every 4 hours as needed for up to a maximum of 5 days
Study: NCT01507363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for 7 days, starting on the day of surgery
Study: NCT00800007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANZ-521
Description: 3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
Study: NCT00622856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education
Description: 5 sessions with diabetes nurse
Study: NCT00681291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair with Ultrapro
Description: surgical mesh (15x15cm) to support Lichtenstein repair
Study: NCT00874536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid alpha-linolenic acid (ALA)
Description: 3 grams of ALA-containing plant oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00891631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSBIRT
Description: Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSBIRT/TE
Description: Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
Study: NCT00800007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
Study: NCT02755077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head rotation during mask ventilation
Description: Patient's head position is axially rotated 45 degrees to the right.
Study: NCT02897583

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: YAG vitreolysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: YAG vitreolysis
Study: NCT05910112

Intervention type: PROCEDURE
Intervention: Pleural interventions
Description: eg thoracocentesis, chest drain, indwelling pleural catheters, thoracoscopy
Study: NCT01715792

Intervention type: OTHER
Intervention: Data collection
Description: Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
Study: NCT00850434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified AutoSet Algorithm
Description: The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified AutoSet Algorithm
Description: The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard AutoSet Algorithm
Description: The standard AutoSet used for treatment of OSA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard AutoSet Algorithm
Description: The standard AutoSet used for treatment of OSA
Study: NCT04351828

Intervention type: PROCEDURE
Intervention: Blood draw once a time
Description: Investigation of intestinal permeability by measuring serum zonulin levels in blood sample

Intervention type: PROCEDURE
Intervention: Blood draw once a time
Description: Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
Study: NCT04467671

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tissue Engineered Vascular Grafts
Description: Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
Study: NCT00681291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair with Strattice
Description: Surgical mesh (10x16) used to support Lichtenstein repair
Study: NCT00544466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m2 day -7 through day -3 prior to transplant
Study: NCT00623194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
Study: NCT02059538

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver

Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan

Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan

Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan

Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan

Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan

Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan

Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Study: NCT00513279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334
Description: GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334
Description: GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 matching placebo tablets
Description: GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 matching placebo tablets
Description: GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
Study: NCT04914455

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography and transhepatic inferior vena cava assessment using ultrasound.
Description: For all participant :~* Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~* Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~* Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;
Study: NCT03651882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
Study: NCT00544466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 day -2 prior to transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Cells infused on Day 0 of transplant regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
Study: NCT02059538

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Study: NCT03424044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Dual Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Single Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XeriSol glucagon
Description: XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
Study: NCT00674687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2-weeks placebo then gabapentin
Description: Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
Study: NCT02059538

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Study: NCT00674687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-week placebo then gabapentin
Description: Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
Study: NCT02903368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Study: NCT03651882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin is given 0.1mg intravenously as a bolus after delivery.